Alphamab Oncology (FRA:3NK) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3NK Alphamab Oncology FRA:3NK
55 GF Score
Price €0.88
GF Value €0.82
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:3NK
55GF Score
Alphamab Oncology FRA:3NK
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.

Key valuation signals for FRA:3NK:

  • Short Ratio:
  • GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for FRA:3NK

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.82
GF Value